期刊文献+

成纤维细胞生长因子受体家族在头颈鳞癌细胞中的表达及定位 被引量:6

Expression and localization of FGFR family in squamous cell carcinoma of head and neck
下载PDF
导出
摘要 目的:探讨成纤维细胞生长因子受体在头颈鳞癌细胞中的表达及其定位。方法:提取10种头颈鳞癌细胞系蛋白,采用Western印迹技术检测FGFR家族成员的表达;利用免疫荧光技术检测FGFR各型在SCC25和HN6细胞中的表达位置。应用Image J软件测量免疫印迹条带灰度值,Graph Pad Prism 5.01对灰度值结果进行统计学分析。结果:在10株头颈鳞癌细胞细中,6株表达FGFR1。FGFR2、3、4均在10株头颈鳞癌细胞细中表达。FGFR1、2、4表达于细胞核及细胞质,FGFR3仅表达于细胞质。结论:FGFR在头颈鳞癌细胞细中共表达,可能与头颈鳞癌的发生、发展有关;FGFR家族不同亚型在头颈鳞癌细胞的表达定位存在差异。 PURPOSE: To investigate the expression and localization of FGFR family in squamous cell carcinoma of head and neck (SCCHN) cell lines. METHODS: Total protein was extracted from 10 SCCHN cell lines and the expression of FGFR was detected by Western blot. The localization of FGFR was further demonstrated by immunofluorescence staining in SCC25 and HN4 cell lines. Gray value was measured by Image J. GraphPad Prism 5.01 software package was used for data processing and analysis. RESULTS: FGFR1 expression was detected in 6/10 cell lines and FGFR2, 3, 4 was detectable in all cell lines. The expression of FGFR1, 2, 4 was mainly in the nucleus and cytoplasm while FGFR3 was predominantly localized in cytoplasm. CONCLUSIONS: FGFR shows co-expression in SCCHN cell lines, which may be associated with the tumorigenesis and development of SCCHN.
出处 《上海口腔医学》 CAS CSCD 2016年第5期517-521,共5页 Shanghai Journal of Stomatology
基金 国家自然科学基金(81202131)
关键词 成纤维细胞生长因子受体 鳞癌 头颈部 Fibroblast growth factor receptors Squamous cell carcinoma Head and neck
  • 相关文献

参考文献17

  • 1Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer. 2010, 10(2): 116-129.
  • 2Dieci MV, Arnedos M, Andre F, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a hiologic rationale to medical perspectives [J]. Cancer Discov, 2013, 3(3): 264-279.
  • 3Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis[J], Cytokine Growth Factor Rev. 2005, 16(2): 179- 186.
  • 4Haddad RI, Shin DM. Recent advances in head and neck cancer [J]. N Engl J Med, 2008, 359(11): 1143-1154.
  • 5Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer [J]. Clin Cancer Res, 2012, 18(7): 1855-1862.
  • 6Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes [J]. Nature, 2007, 446(7132): 153-158.
  • 7Hagel M, Miduturu C, Sheets M, et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway [J]. Cancer Discov, 2015, 5(4): 424-437.
  • 8Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family [J]. Cancer Res, 2012, 72(8): 2045-2056.
  • 9Vairaktaris E, Ragos V, Yapijakis C, et al. FGFR-2 and -3 play an important role in initial stages of oral oneogenesis [J]. Anticancer Res, 2006, 26(6B): 4217-4221.
  • 10Nguyen PT, Tsunematsu T, Yanagisawa S, et al. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-I[J]. Br J Cancer, 2013, 109(8): 2248-2258.

同被引文献37

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部